{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:03:41Z","timestamp":1783569821205,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1D1A1B07044329"],"award-info":[{"award-number":["2018R1D1A1B07044329"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clml.2021.01.020","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T09:33:20Z","timestamp":1612344800000},"page":"e521-e529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"21","author":[{"given":"Hyejin","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Young","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-8323","authenticated-orcid":false,"given":"Jangik I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.01.020_bib1","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2021.01.020_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.01.020_bib3","first-page":"646","article-title":"[Tyrosine kinase inhibitors (TKI): a new revolution in the treatment of chronic myeloid leukemia (CML)]","volume":"149","author":"Aviles-Vazquez","year":"2013","journal-title":"Gac Med Mex"},{"key":"10.1016\/j.clml.2021.01.020_bib4","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.31232","article-title":"Dasatinib dose management for the treatment of chronic myeloid leukemia","volume":"124","author":"Talpaz","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.01.020_bib5","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.020_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12185-019-02805-9","article-title":"Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia","volume":"111","author":"Shin","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2021.01.020_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000111777","article-title":"Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area","volume":"118","author":"Park","year":"2007","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2021.01.020_bib9","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure\u2013response analysis of a phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.clml.2021.01.020_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3727\/096504015X14452563485986","article-title":"What is the optimal dose and schedule for dasatinib in chronic myeloid leukemia: two case reports and review of the literature","volume":"23","author":"Jamison","year":"2016","journal-title":"Oncol Res"},{"key":"10.1016\/j.clml.2021.01.020_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.020_bib12","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3109\/10428194.2013.866663","article-title":"Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase","volume":"55","author":"Chuah","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.01.020_bib13","first-page":"303","article-title":"A\u00a0formula to estimate the approximate surface area if height and weight be known 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"10.1016\/j.clml.2021.01.020_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","article-title":"Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","volume":"150","author":"Santos","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.020_bib16","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.020_bib17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.01.020_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-011-0729-7","article-title":"The safety profile of imatinib in CML and GIST: long-term considerations","volume":"86","author":"Thanopoulou","year":"2012","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.clml.2021.01.020_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clml.2021.01.020_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clml.2021.01.020_bib21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s10147-018-1300-9","article-title":"Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study","volume":"23","author":"Mizuta","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.020_bib22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1097-0142(197808)42:2<669::AID-CNCR2820420238>3.0.CO;2-L","article-title":"Endocrine influences on survival from malignant melanoma","volume":"42","author":"Shaw","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.01.020_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccr.2013.11.011","article-title":"Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma","volume":"25","author":"Hou","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.01.020_bib24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/cam4.1436","article-title":"Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia","volume":"7","author":"Noh","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.01.020_bib25","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3109\/10428194.2015.1113278","article-title":"Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose\u2013response relationship analyses","volume":"57","author":"Noh","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.01.020_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.14783","article-title":"Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors","volume":"182","author":"Molica","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.020_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00411-013-0507-4","article-title":"Sex differences in the incidence of chronic myeloid leukemia","volume":"53","author":"Radivoyevitch","year":"2014","journal-title":"Radiat Environ Biophys"},{"key":"10.1016\/j.clml.2021.01.020_bib28","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.020_bib29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2403756","article-title":"Gender aspects in chronic myeloid leukemia: long-term results from randomized studies","volume":"19","author":"Berger","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.020_bib30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/aps.2010.79","article-title":"Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clml.2021.01.020_bib31","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.01.020_bib32","first-page":"237","article-title":"Dasatinib daily dose opitmization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized OPTIM DASATINIB trial","volume":"99","author":"Rousselot","year":"2014","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:15Z","timestamp":1778838555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2152265021000380"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}